Ironwood Pharmaceuticals, Inc.

Good morning. My name is Rob and I will be your conference operator today. At this time, I would like to welcome everyone to the Ironwood Pharmaceuticals third quarter 2021 investor update call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this session, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question, again, press the star 1. Thank you. Matt Roach, Director of Investor Relations, you may begin your conference.

Thank you, Rob. Good morning, and thanks for joining us for our third quarter 2021 investor update. Our press release crossed the wire this morning and can be found on our website. Today's call and accompanying slides include forward-looking statements. Such statements involve risks and uncertainties that may cause actual results to differ materially. A discussion of these statements and risk factors is available on the current State Harbor Statement slide, as well as under the heading Risk Factors in our quarterly report on Form 10-Q for the quarter ended June 30th, 2021, and in our future S&T filings. All forward-looking statements speak as of the date of this presentation, and we undertake no obligation to update such statements. Also included are non-GAAP financial measures, which should be considered only as a supplement to, and not a substitute for, or superior to, GAAP measures. To the extent applicable, please refer to the tables at the end of our press release for reconciliations of these measures to the most directly comparable GAAP measures. During today's call, Tom LaCour, our CEO, will provide an update on progress towards our strategic priorities and commercial performance of Lydess. Mike Schetzlein, our Chief Medical Officer, will provide an update on our pipeline, including the option agreement with Core Pharmaceuticals that we announced this morning. And Jason Riggard, our Chief Operating Officer, will wrap up the review of our financial results and guidance. We will be referring to slides via the webcast. For those of you dialing in, please go to the events section of our website to access the slides. With that, I will turn the call over to Tom.

Thanks, Matt. Good morning, everyone, and thanks for joining us today. We closed another strong quarter in 2021, driven once again by double-digit Linza's prescription demand growth year over year. This morning, we announced that we've expanded our pipeline by entering into an option agreement with Core Pharmaceuticals, which we'll review in more detail in a few minutes. We're coming out of a terrific American College of Gastroenterology meeting where we presented new findings from a survey on the impact of abdominal symptoms on adult patients with irritable bowel syndrome with constipation. In addition, we gave an oral presentation and presented four other posters, one of which received ACG's Presidential Poster Award. I couldn't be more proud of the team's execution and the work we're doing to advance treatment in GI diseases and redefine standard of care for GI patients. Let's start with a few overview of our strategic imperatives, as well as our strategic priorities. Our strategy starts with maximizing LINDSES. Since launch in 2012, LINDSES continues to experience accelerated demand and widespread acceptance among healthcare practitioners as a leading prescription treatment for adults with IBSC and chronic constipation. In the third quarter, Linza's total prescription demand grew 12% versus the prior year quarter, and new-to-brand prescription growth continued to outpace the market. Next, we are looking to build an innovative portfolio, both through the development of internal assets and through bringing external therapies that target serious organic GI diseases. Mike will be providing an update on our pipeline. Finally, we're committed to delivering sustainable profits and cash flow, We had another impressive quarter on the bottom line and ended this third quarter with $574 million in cash and cash equivalents on the balance sheet. We're taking a thoughtful and disciplined approach to capital allocation in an effort to maximize return to our shareholders as we continue to explore growth opportunities with the same high bar we've always had. Now, I will turn it over to Mike to discuss our pipeline. Mike?